These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8305649)

  • 1. Phosphate kinetics during high-flux hemodialysis.
    DeSoi CA; Umans JG
    J Am Soc Nephrol; 1993 Nov; 4(5):1214-8. PubMed ID: 8305649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hemodialysis membrane type on parathyroid hormone removal.
    Kudlac H; Fielding AM; Williams AJ
    Miner Electrolyte Metab; 1994; 20(5):245-9. PubMed ID: 7700210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.
    DeSoi CA; Sahm DF; Umans JG
    Am J Kidney Dis; 1992 Oct; 20(4):354-60. PubMed ID: 1415203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism.
    De Francisco AL; Amado JA; Prieto M; Alcalde G; Sanz de Castro S; Ruiz JC; Morales P; Arias M
    Nephron; 1994; 66(4):442-6. PubMed ID: 8015649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of reprocessing cuprophane and polysulfone dialyzers on beta 2-microglobulin removal from hemodialysis patients.
    Petersen J; Moore RM; Kaczmarek RG; Singh B; Yeh I; Hamburger S; Kankam M
    Am J Kidney Dis; 1991 Feb; 17(2):174-8. PubMed ID: 1992659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate removal model: an observational study of low-flux dialyzers in conventional hemodialysis therapy.
    Wang M; Li H; Liao H; Yu Y; You L; Zhu J; Huang B; Yuan L; Hao C; Chen J
    Hemodial Int; 2012 Jul; 16(3):363-76. PubMed ID: 22360645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.
    Argilés A; Kerr PG; Canaud B; Flavier JL; Mion C
    Kidney Int; 1993 Mar; 43(3):630-40. PubMed ID: 8455362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease.
    Touchette MA; Patel RV; Anandan JV; Dumler F; Zarowitz BJ
    Am J Kidney Dis; 1995 Sep; 26(3):469-74. PubMed ID: 7645555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis.
    Rudnicki M; Frølich A; Haaber A; Tvedegaard E; Thode J
    Clin Nephrol; 1993 Oct; 40(4):225-9. PubMed ID: 8261680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the hemodialysis adequacy conducted based on low-flux polysulfone dialyzers and high-flux helixone dialyzers].
    Sobaszek-Pitas M; Kopeć J; Krzanowski M; Sułowicz W
    Przegl Lek; 2014; 71(7):384-8. PubMed ID: 25338334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium exposure and removal in chronic hemodialysis patients.
    Sigrist M; McIntyre CW
    J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
    Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
    Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
    McCarthy JT; Jenson BM; Squillace DP; Williams AW
    Am J Kidney Dis; 1997 Apr; 29(4):576-83. PubMed ID: 9100048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients.
    Guh JY; Chen HC; Chuang HY; Huang SC; Chien LC; Lai YH
    Am J Kidney Dis; 2002 Jun; 39(6):1245-54. PubMed ID: 12046038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1.25(OH)2 cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients.
    Boran M; Doruk E; Gönenç F; Cetin S
    Int Urol Nephrol; 1997; 29(2):251-8. PubMed ID: 9241557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of plasma insulin and C-peptide levels with 3 different high-flux dialyzers in diabetic patients on hemodialysis.
    Abe M; Okada K; Maruyama T; Inoshita A; Ikeda K; Uto E; Kikuchi F; Matsumoto K
    Int J Artif Organs; 2008 Oct; 31(10):898-904. PubMed ID: 19009508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iPTH values during hemodialysis: role of ionized Ca, dialysis membranes and iPTH assays.
    D'Amour P; Jobin J; Hamel L; L'Ecuyer N
    Kidney Int; 1990 Aug; 38(2):308-14. PubMed ID: 2402123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Biomarkers of Mineral and Bone Metabolism and Removal of Calcium and Phosphate in Hemodialysis.
    Debowska M; Dai L; Wojcik-Zaluska A; Poleszczuk J; Zaluska W; Lindholm B; Waniewski J
    Blood Purif; 2020; 49(1-2):71-78. PubMed ID: 31726453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.